Sánchez Jorge, Álvarez Leidy, Bedoya Juan, Peñaranda Daniel, Vanegas Gustavo, Celis Carlos, Morales Edison, García Elizabeth, Peñaranda Augusto
Group of Clinical and Experimental Allergy, Hospital "Alma Mater de Antioquia", University of Antioquia, Medellín, Colombia.
Group "ciencias de la vida y de la salud escuela de graduados", CES university, Medellín, Colombia.
World Allergy Organ J. 2024 Oct 7;17(10):100953. doi: 10.1016/j.waojou.2024.100953. eCollection 2024 Oct.
Guidelines for chronic rhinosinusitis (CRS) propose total IgE and eosinophils as important biomarkers to identify type-2 inflammation. Despite the fact that specific IgE (sIgE) have been identified as a clinical predictor in some type-2 diseases for different clinical outcomes, its role in CRS has yet to be explored in detail.
To describe systemic and local sIgE in CRS and explore its possible association with clinical outcomes using nasal challenge tests (NCT).
In CRS patients, we measure total IgE, serum sIgE (SsIgE) and nasosinusal sIgE (NsIgE) against 9 allergenic sources; Der p, Der f, Blo t, Can f, Fel d, Per a, grasses, Staphylococcus enterotoxin A, and B. NCT was done using the allergen with the higher sIgE prevalence (Der p).
A total of 174 patients were included. Prevalence of SsIgE was 52.8% and NsIgE 46.5%; Der p was the principal allergen for SsIgE and NsIgE. The presence of nasal polyps, asthma comorbidity, NSAID hypersensitivity, and hyposmia, were significantly associated with the presence of SsIgE and NsIgE but not with total IgE. NCT-Der p was performed in 73 CRS patients, being positive in 33 (45.2%). SsIgE have the best diagnostic accuracy (79.4%) to predict NCT results (NsIgE 67.5% total IgE 52%).
Specific IgE is a better biomarker in CRS than total IgE. Patients with clinically relevant SsIgE have a pheno-endotype associated with different clinical outcomes. Considering the clinical relevance of SsIgE demonstrated by NCT, interventions like allergen immunotherapy in CRS must be study.
慢性鼻-鼻窦炎(CRS)指南提出,总IgE和嗜酸性粒细胞是识别2型炎症的重要生物标志物。尽管特异性IgE(sIgE)已被确定为某些2型疾病不同临床结局的临床预测指标,但其在CRS中的作用尚未得到详细探讨。
描述CRS患者的全身和局部sIgE,并通过鼻激发试验(NCT)探讨其与临床结局的可能关联。
在CRS患者中,我们检测了针对9种变应原的总IgE、血清sIgE(SsIgE)和鼻鼻窦sIgE(NsIgE);分别为屋尘螨、粉尘螨、柏氏禽刺螨、猫毛、猫皮屑、豚草、禾本科植物、金黄色葡萄球菌肠毒素A和B。使用sIgE患病率较高的变应原(屋尘螨)进行NCT。
共纳入174例患者。SsIgE患病率为52.8%,NsIgE患病率为46.5%;屋尘螨是SsIgE和NsIgE的主要变应原。鼻息肉、合并哮喘、非甾体抗炎药超敏反应和嗅觉减退的存在与SsIgE和NsIgE的存在显著相关,但与总IgE无关。73例CRS患者进行了屋尘螨激发试验,其中33例(45.2%)呈阳性。SsIgE预测NCT结果的诊断准确性最高(79.4%)(NsIgE为67.5%,总IgE为52%)。
在CRS中,特异性IgE是比总IgE更好的生物标志物。具有临床相关性的SsIgE患者具有与不同临床结局相关的表型-内型。考虑到NCT证实的SsIgE的临床相关性,必须研究CRS中变应原免疫治疗等干预措施。